Abivax (ABVX) EBITDA (2022 - 2026)
Abivax (ABVX) posted quarterly EBITDA of -$65.8 million for Q1 2026, down 32.59% year-over-year from -$97.7 million in Q1 2025, and up 21.12% on a QoQ basis from -$83.5 million in Q4 2025.
Abivax (ABVX) EBITDA (2022 - 2026) Analysis & Trends
Abivax (ABVX) has reported EBITDA for 5 consecutive years, with -$65.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 32.59% year-over-year to -$65.8 million; the TTM figure through Mar 2026 stood at -$296.3 million (down 57.12% YoY), while the FY2025 annual figure was -$286.5 million, down 54.96% from the prior year.
- EBITDA came in at -$65.8 million for Q1 2026 at Abivax, up from -$83.5 million in the prior quarter.
- The five-year high for EBITDA was -$38.0 million in Q2 2024, with the low at -$137.1 million in Q4 2023.
- Average EBITDA over 5 years is -$67.0 million, with a median of -$55.1 million recorded in 2024.
- Across the five-year window, EBITDA tumbled 107.34% in 2023 and jumped 66.62% in 2024, its largest moves.
- Year by year, EBITDA stood at -$66.1 million in 2022, then slumped by 107.34% to -$137.1 million in 2023, then surged by 66.62% to -$45.8 million in 2024, then slumped by 82.41% to -$83.5 million in 2025, then rose by 21.12% to -$65.8 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$65.8 million, -$83.5 million, and -$94.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | -106.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -14.44 Mn |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 249.90 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 1.14 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -4.91 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 661.60 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 394.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 201.19 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | -445.22 Mn |
| 10 | Abivax | - | - | - | -65.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.83 Mn |
| Dec 31, 2025 | -83.45 Mn |
| Sep 30, 2025 | -94.36 Mn |
| Jun 30, 2025 | -52.63 Mn |
| Mar 31, 2025 | -49.65 Mn |
| Dec 31, 2024 | -45.75 Mn |
| Sep 30, 2024 | -55.12 Mn |
| Jun 30, 2024 | -38.04 Mn |
| Mar 31, 2024 | -48.53 Mn |
| Dec 31, 2023 | -137.07 Mn |
| Dec 31, 2022 | -66.11 Mn |